Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Paul M. Clément et al.|Annals of Oncology|2020Cited by 365
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Lisa Licitra, Robert L. Ferris, Robert I. Haddad et al.|Journal of Clinical Oncology|2019Cited by 39
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Ricard Mesı́a, Weimin Li et al.|Clinical Cancer Research|2023Cited by 30